AGM/EGMJun 4, 2026, 04:12 PM
Kura Oncology Stockholders Approve Equity Plan Amendments, Elect Directors
AI Summary
Kura Oncology, Inc. held its Annual Meeting of Stockholders where shareholders approved amendments to the 2014 Equity Incentive Plan and the 2015 Employee Stock Purchase Plan, increasing the number of authorized shares for each. The company also saw the election of three Class III directors and the ratification of Ernst & Young LLP as its independent auditor. Additionally, advisory votes on executive compensation and the frequency of such votes were passed.
Key Highlights
- Stockholders approved the Amended 2014 Equity Incentive Plan, increasing authorized shares by 6.5 million.
- Stockholders approved the Amended 2015 Employee Stock Purchase Plan, increasing authorized shares by 2.5 million.
- Diane Parks, Mary T. Szela, and Michael J. Vasconcelles, M.D. were elected as Class III directors.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
- Stockholders approved, on an advisory basis, the compensation paid to named executive officers ('Say-on-Pay').
- Stockholders indicated a preference for annual advisory votes on executive compensation.
Price Impact
More from KURA